Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA

Lysogene (LYS.PA) (FR0013233475 – LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced the completion of enrollment in its “Sanfilippo A Multi-national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).